Cellectar Biosciences
CLRB
29 hedge funds and large institutions have $9.08M invested in Cellectar Biosciences in 2026 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 4 closing their positions.
1,017% more capital invested
Capital invested by funds: $813K → $9.08M (+$8.27M)
250% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 4
200% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 2
53% more funds holding
Funds holding: 19 → 29 (+10)
33.46% more ownership
Funds ownership: 7.33% → 40.79% (+33%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CP
Caligan Partners
New York
|
+$1.31M |
| 2 |
SC
Stempoint Capital
New York
|
+$993K |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
+$900K |
| 4 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$687K |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$615K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$35.3K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$18.3K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.01K |
| 4 |
Vanguard Global Advisers
Malvern,
Pennsylvania
|
-$1.43K |
| 5 |
BlackRock
New York
|
-$28 |
CLRB Hedge Fund Activity: Q2 2026 in Review
29 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q2 2026, worth a combined $9.08M — up 1,017% from $813K a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new CLRB positions and 4 closed out — a net gain of 10 holders — while 6 added to existing stakes and 2 trimmed.
The largest buyer was Caligan Partners, opening a new position worth an estimated $1.31M. The largest seller was Warberg Asset Management, exiting entirely with an estimated $35.3K sold.
- 29 institutional investors held Cellectar Biosciences (CLRB) as of Q2 2026, up from 19 in Q1 2026.
- Funds reported $9.08M of Cellectar Biosciences stock for Q2 2026, up 1,017% quarter-over-quarter.
- 14 funds opened new Cellectar Biosciences positions in Q2 2026 and 4 closed out, a net change of +10 holders.
- The largest Cellectar Biosciences buyer in Q2 2026 was Caligan Partners, an estimated $1.31M added.
- The largest Cellectar Biosciences seller in Q2 2026 was Warberg Asset Management, an estimated $35.3K sold.
Based on aggregated 13F filings for Q2 2026.